On the Lengths, Colours and Ages of Bars

In an effort to obtain further observational evidences for secular evolution processes in galaxies, as well as observational constraints to current theoretical models of secular evolution, we have used BVRI and Ks images of a sample of 18 barred galaxies to measure the lengths and colours of bars, create colour maps and estimate global colour gradients. In addition, applying a method we developed in a previous article, we could distinguish for 7 galaxies in our sample those whose bars have been recently formed from the ones with already evolved bars. We estimated an average difference in the optical colours between young and evolved bars that may be translated to an age difference of the order of 10 Gyr, meaning that bars may be long standing structures. Moreover, our results show that, on average, evolved bars are longer than young bars. This seems to indicate that, during its evolution, a bar grows longer by capturing stars from the disk, in agreement with recent numerical and analytical results.Comment: To appear in Galaxy Evolution Across the Hubble Time, proceedings of the IAU Symp. 235, F. Combes and J. Palous (eds.); 1 page; the poster can be found at http://www.mpa-garching.mpg.de/~dimitri/iauga.pd

The role of antibiotics in the treatment of chronic prostatitis: A consensus statement

Practical guidelines for the diagnosis and treatment of chronic prostatitis are presented. Chronic prostatitis is classified as chronic bacterial prostatitis (culture-positive) and chronic inflammatory prostatitis (culture-negative). If chronic bacterial prostatitis is suspected, based on relevant symptoms or recurrent UTIs, underlying urological conditions should be excluded by the following tests: rectal examination, midstream urine culture and residual urine. The diagnosis should be confirmed by the Meares and Stamey technique. Antibiotic therapy is recommended for acute exacerbations of chronic prostatitis, chronic bacterial prostatitis and chronic inflammatory prostatitis, if there is clinical, bacteriological or supporting immunological evidence of prostate infection. Unless a patient presents with fever, antibiotic treatment should not be initiated immediately except in cases of acute prostatitis or acute episodes in a patient with chronic bacterial prostatitis. The work-up, with the appropriate investigations should be done first, within a reasonable time period which, preferably, should not be longer than 1 week. During this period, nonspecific treatment, such as appropriate analgesia to relieve symptoms, should be given. The minimum duration of antibiotic treatment should be 2-4 weeks. If there is no improvement in symptoms, treatment should be stopped and reconsidered. However, if there is improvement, it should be continued for at least a further 2-4 weeks to achieve clinical cure and, hopefully, eradication of the causative pathogen. Antibiotic treatment should not be given for 6-8 weeks without an appraisal of its effectiveness. Currently used antibiotics are reviewed. Of these, the fluoroquinolones ofloxacin and ciprofloxacin are recommended because of their favourable antibacterial spectrum and pharmacokinetic profile. A number of clinical trials are recommended and a standard study design is proposed to help resolve some outstanding issues

Robotic intracorporeal urinary diversion: practical review of current surgical techniques

In this practical review, we discuss current surgical techniques reported in the literature to perform Intracorporeal Urinary Diversion (ICUD) after Robotic Radical Cystectomy (RARC), emphasizing criticisms of single approaches and making comparisons with Extracorporeal Urinary Diversion (ECUD). Although almost 97% of all RARCs use an ECUD, ICUD is gaining in popularity, in view of its potential benefits (i.e., decreased bowel exposure, etc.), although there are a few studies comparing ICUD and ECUD. Analysing single experiences and the data from recent metanalyses, we emphasize the current critiques to ICUD, stressing particular technical details which could reduce operative time, lowering the postoperative complications rate, and improving functional outcomes. Only analysis of long-term follow-up data from large-scale homogeneous series can ascertain whether robotic intracorporeal urinary diversion is superior to other approaches

On the precision of chiral-dispersive calculations of ππ\pi\pi scattering

We calculate the combination $2a_0^{(0)}-5a_0^{(2)}$ (the Olsson sum rule) and the scattering lengths and effective ranges $a_1$, $a_2^{(I)}$ and $b_1$, $b_2^{(I)}$ dispersively (with the Froissart--Gribov representation) using, at low energy, the phase shifts for $\pi\pi$ scattering obtained by Colangelo, Gasser and Leutwyler (CGL) from the Roy equations and chiral perturbation theory, plus experiment and Regge behaviour at high energy, or directly, using the CGL parameters for $a$s and $b$s. We find mismatch, both among the CGL phases themselves and with the results obtained from the pion form factor. This reaches the level of several (2 to 5) standard deviations, and is essentially independent of the details of the intermediate energy region ($0.82\leq E\leq 1.42$ GeV) and, in some cases, of the high energy behaviour assumed. We discuss possible reasons for this mismatch, in particular in connection with an alternate set of phase shifts.Comment: Version to appear in Phys. Rev. D. Graphs and sum rule added. Plain TeX fil

Ansiedad competitiva y clima motivacional en jóvenes futbolistas de competición, en relación con las habilidades y el rendimiento percibido por sus entrenadores

En este estudio se analizan las relaciones existentes entre la ansiedad competitiva (en sus facetas cognitiva y somática) y el clima motivacional percibido (de ego y de maestría) en una población de 54 jóvenes futbolistas decompetición de edad media de 9,45 años, respecto de la percepción de sus habilidades y rendimiento deportivos por parte de sus 4 entrenadores, que también participaron en el estudio. Para ello se les administró las versiones españolas del SAS-2 (Sport Anxiety Scale-2, Smith, Smoll, Cumming y Grossbard, 2006) y el MCSYS (Motivational Climate Scale for Youth Sports,Smith, Cumming y Smoll, 2008), así como dos escalas ad hoc para evaluar la percepción de su habilidad y rendimiento. Los resultados muestran, por una parte, que los jóvenes futbolistas perciben y discriminan claramente los climas motivacionales, que se distribuyen casi al 50% entre ego y maestría; por otra, que aparece ansiedad competitiva, aunque más cognitiva que somática, y que no existe relación significativa con las percepciones de habilidad y rendimiento por parte de los entrenadores. Finalmente, estos resultados se discuten y se comparan con otros similares en poblaciones preadolescentesThis study analysed the relationships between competitive anxiety (both cognitive and somatic) and perceived motivational climate (ego and mastery) in 54 young competitive soccer players (mean age: 9.45 years), related to their four coaches' perceptions of the soccer players' skills and performance. We administered the Spanish versions of the SAS-2 (Sport Anxiety Scale-2, Smith, Smoll, Cumming and Grossbard, 2006) and the MCSYS (Motivational Climate Scale for Youth Sports, Smith, Cumming and Smoll, 2008), along with two ad hoc scales to evaluate perceived skills and performance.The results show that 1) young players perceived and discriminated clearly between motivational climates (which were more or less equally distributed between ego and mastery orientations), 2) some performance-related anxiety (mostly cognitive rather than somatic) appeared and 3) no significant relationships were found between their coaches' perceptions of their skills and their performance. Lastly, the results are discussed and compared with similar results from preadolescent player

Association of MC1R Variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study

<p><b>Background</b> Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma. Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes, and some variants of the melanocortin-1 receptor gene (MC1R), which is known to have a role in the pigmentation process. However, investigation of the associations of both MC1R variants and host phenotypes with melanoma risk has been limited.</p> <p><b>Methods</b> We included 815 CDKN2A mutation carriers (473 affected, and 342 unaffected, with melanoma) from 186 families from 15 centers in Europe, North America, and Australia who participated in the Melanoma Genetics Consortium. In this family-based study, we assessed the associations of the four most frequent MC1R variants (V60L, V92M, R151C, and R160W) and the number of variants (1, ≥2 variants), alone or jointly with the host phenotypes (hair color, propensity to sunburn, and number of nevi), with melanoma risk in CDKN2A mutation carriers. These associations were estimated and tested using generalized estimating equations. All statistical tests were two-sided.</p> <p><b>Results</b> Carrying any one of the four most frequent MC1R variants (V60L, V92M, R151C, R160W) in CDKN2A mutation carriers was associated with a statistically significantly increased risk for melanoma across all continents (1.24 × 10−6 ≤ P ≤ .0007). A consistent pattern of increase in melanoma risk was also associated with increase in number of MC1R variants. The risk of melanoma associated with at least two MC1R variants was 2.6-fold higher than the risk associated with only one variant (odds ratio = 5.83 [95% confidence interval = 3.60 to 9.46] vs 2.25 [95% confidence interval = 1.44 to 3.52]; Ptrend = 1.86 × 10−8). The joint analysis of MC1R variants and host phenotypes showed statistically significant associations of melanoma risk, together with MC1R variants (.0001 ≤ P ≤ .04), hair color (.006 ≤ P ≤ .06), and number of nevi (6.9 × 10−6 ≤ P ≤ .02).</p> <p><b>Conclusion</b> Results show that MC1R variants, hair color, and number of nevi were jointly associated with melanoma risk in CDKN2A mutation carriers. This joint association may have important consequences for risk assessments in familial settings.</p&gt

Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy

High risk of recurrence/progression bladder tumours is treated with Bacillus Calmette-Guérin (BCG) immunotherapy after complete resection of the tumour. Approximately 75% of these tumours express the uncommon carbohydrate antigen sialyl-Tn (Tn), a surrogate biomarker of tumour aggressiveness. Such changes in the glycosylation of cell-surface proteins influence tumour microenvironment and immune responses that may modulate treatment outcome and the course of disease. The aim of this work is to determine the efficiency of BCG immunotherapy against tumours expressing sTn and sTn-related antigen sialyl-6-T (s6T). METHODS: In a retrospective design, 94 tumours from patients treated with BCG were screened for sTn and s6T expression. In vitro studies were conducted to determine the interaction of BCG with high-grade bladder cancer cell line overexpressing sTn. RESULTS: From the 94 cases evaluated, 36 had recurrence after BCG treatment (38.3%). Treatment outcome was influenced by age over 65 years (HR=2.668; (1.344-5.254); P=0.005), maintenance schedule (HR=0.480; (0.246-0.936); P=0.031) and multifocality (HR=2.065; (1.033-4.126); P=0.040). sTn or s6T expression was associated with BCG response (P=0.024; P<0.0001) and with increased recurrence-free survival (P=0.001). Multivariate analyses showed that sTn and/or s6T were independent predictive markers of recurrence after BCG immunotherapy (HR=0.296; (0.148-0.594); P=0.001). In vitro studies demonstrated higher adhesion and internalisation of the bacillus to cells expressing sTn, promoting cell death. CONCLUSION: s6T is described for the first time in bladder tumours. Our data strongly suggest that BCG immunotherapy is efficient against sTn- and s6T-positive tumours. Furthermore, sTn and s6T expression are independent predictive markers of BCG treatment response and may be useful in the identification of patients who could benefit more from this immunotherapy